Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance understanding of cellular ...

X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one ...

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...

This study provides a valuable new resource to investigate the molecular basis of the particular features characterizing the pipefish embryo. The authors found both unique and shared gene expression ...

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

The European single cell multiomics market, valued at $527.9 million in 2021, is poised for significant growth, with projections indicating an annual growth rate of 18.0% over the decade from 2021 to ...

PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...